

CURRICULUM VITAE
Andrew Hsu, MD, FACP

Business Address: Rhode Island Hospital, APC Building
593 Eddy Street
Providence, RI 02906
Business Telephone #: (401) 444-6654
Business Fax #: (401) 444-4184
Electronic Mail Address: andrew_hsu1@brown.edu

EDUCATION

Undergraduate University of California, Berkeley; BA, English Literature, 2008
Medical School Ross University School of Medicine, MD, 2014, High Honors

POSTGRADUATE TRAINING

Residency University of Massachusetts Medical School 2014-2017
Fellowship Brown University Hematology/Oncology Fellowship 2018-2021

POSTGRADUATE HONORS AND AWARDS

- Ross University School of Medicine Dean's List, Fall 2010, Spring 2011, Summer 2011, Fall 2011
- Inpatient Quality Improvement at University of Massachusetts Medical School Research Day 2017, **First Prize**
- Outstanding House Officer Educator Award 2018
- Positive Champion of the Learning Environment of Alpert Medical School 2019
- *Invited Fellowship* in the American College of Physicians, July 2024

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

- Rhode Island State Medical License, 2020-present
- Massachusetts State Medical License, 2017-2022
- American Board of Internal Medicine (ABIM), Internal Medicine, 2018
- American Board of Internal Medicine (ABIM), Hematology, 2022
- Education Commission for Foreign Medical Graduates (ECFMG) Certification, 2014

ACADEMIC APPOINTMENTS

- Assistant Professor of Medicine, *Clinician-Educator*, Warren Alpert Medical School of Brown University, 2021-present
- Chief Fellow, Brown University Hematology/Oncology, 2020-2021
- Clinical Instructor, University of Massachusetts Medical School, 2017-2018
- Chief Resident, University of Massachusetts Internal Medicine, 2017-2018

HOSPITAL APPOINTMENTS

- Director of Thrombosis and Hemostasis, Brown University Health Cancer Institute, 2022-present
- Attending Physician, Rhode Island Hospital, 2021-present
- Attending Physician, The Miriam Hospital, 2021-present

HOSPITAL COMMITTEES

- Brown University Health Antithrombotic Subcommittee of the Pharmacy & Therapeutics *Co-Chair*, Rhode Island Hospital/Miriam Hospital/Newport Hospital, 2022-present
- Institutional Review Board (IRB)
Primary/Voting Member, The Miriam Hospital (IRB #3), 2021-2024
- Pulmonary Embolism Disposition from the Emergency Department (PEDED)
Committee member, 2022
- Hematology/Oncology Fellowship at Brown University Program Evaluation Committee
Co-Chair, Rhode Island Hospital/The Miriam Hospital, 2021-2022

EDITORIAL BOARDS

- Journal of Brown Hospital Medicine (JBHM)
Associate Editor, 2022-present
- Rhode Island Medical Journal (RIMJ)
Advisory Editorial Board, 2024-present

AD-HOC REVIEWER

- Journal of Supportive Care in Cancer, 2019-present
- Rhode Island Medical Journal, 2021-present
- Annals of Translational Medicine, 2021
- Annals of Medicine, 2020
- Therapeutic Advances in Hematology, 2020

TEACHING EXPERIENCE and RESPONSIBILITIES

- Subspecialty Clerkship Rotation for Third Year Brown Medical Students
Preceptor, 2023-present
- Hematology/Oncology Fellowship Hematology Lecture Series
Lecturer, 2021-present
- Internal Medicine Residency Conference Lectures
Lecturer, 2021-present
- BIOL3672: IMS-IV: Integrated Hematology Course
Faculty, 2019-present
- Worcester Free Clinic Coalition, Greenwood Street
Preceptor, 2015-2017
- Ross University School of Medicine, Department of Anatomy
Anatomy Teaching Assistant, 2011
- Ross University School of Medicine, Academic Success
Academic Peer Tutor, 2011

PROFESSIONAL SOCIETY MEMBERSHIP

- Member, American Society of Hematology, 2018-present
- Associate Member, International Society of Thrombosis and Haemostasis, 2021-present
- Member, American Society of Clinical Oncology, 2018-2024
- *Fellow*, American College of Physicians, 2014-present

RESEARCH ACTIVITIES

SPONSORED TRIALS

- Phase III: Randomized study of ivalumab versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia
Sponsor: Novartis
Role: Site Primary Investigator
- Phase III: Randomized study to evaluate the safety and tolerability of investigator's choice thrombopoietin receptor agonist (TPO-RA) with ivalumab in patients with primary immune thrombocytopenia (ITP) previously treated with at least one line of therapy
Sponsor: Novartis
Role: Site Primary Investigator
- Phase III: Randomized study to assess the efficacy and safety of ruxitinib versus placebo in participants with warm autoimmune hemolytic anemia (wAIHA)
Sponsor: Sanofi
Role: Site Primary Investigator

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. **Hsu A**, Belkin E, Han S, Pellish R. Tamoxifen-associated portal vein thrombosis causing severe oesophageal variceal bleeding. *BMJ Case Rep*. 2015 Aug 27;2015. PMID: 26315359
2. **Hsu A**, Han S. Synchronous neuroendocrine tumor and non-small cell lung cancer in neurofibromatosis type 1. *Clin Case Rep*. 2015;3(12):990-6. PMID: 26734134
3. Han S, **Hsu A**, Bui R, Ellison RT. A Fatal Case of Levamisole-Induced Vasculitis. *Skin Diseases and Skin Care* 2016; 1(1) 1-3.
4. Han S, **Hsu A**, Wassef WY. An Update in the Endoscopic Management of Gastric Cancer. *Curr Opin Gastroenterol*. 2016 Nov;32(6): 492-500. PMID: 27662061
5. **Hsu A**, Gagnier M, Ryer E, Salhab M, Rosmarin AG. Hypercalcemia due to Primary Hepatic Lymphoma. *Case Rep Hematol*. 2016:1876901. PMID: 28116183
6. Salhab M, **Hsu A**, Ryer E, Appiah J, Switzer B. Microangiopathic Hemolytic Anemia in Pregnancy. *Transfus Apher Sci*. 2017 Jun;56(3):354-56. PMID: 28283300
7. Salhab M, Ellis D, **Hsu A**, Switzer B. Budd-Chiari Syndrome in a Patient with JAK-2 Mutation without Myeloproliferative Disorder. *Med Case Rep*. 2017, 3:1.
8. **Hsu A**, Ryer E, Gagnier M, Salhab M. Hyperviscosity Syndrome Provoking Heart Failure in a Patient with Waldenström Macroglobinemia. *MOJ Clin Med Case Rep*. 6(6): 00180.
9. Mendelson L, Hsu E, Chung H, **Hsu A**. Primary Cardiac Lymphoma: Importance of Tissue Diagnosis. *Case Rep Hematol*. 2018:6192452. PMID: 30147970
10. Holzwanger EA, Alam Z, Hsu E, **Hsu A**, Mangano M, Kathman DL. A Case of Granulocytic Sarcoma or Extramedullary Acute Myelomonocytic Leukemia of the Gallbladder. *Am J Case Rep*. 2018 Oct 24;19:1262-6. PMID: 30352989
11. **Hsu A**, Ulici V. Verruconis gallopava in a patient with myelofibrosis on ruxitinib. *Blood*. 2020 April 2;135(14):1189. PMID: 32243521
12. **Hsu A**, Mendelson L, Almhanna K. Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies. *R I Med J (2013)*. 2020 April 1;103(3):33-7. PMID: 32236159

13. **Hsu A**, Freeman N. The fertile field of “isomopic” immune dysregulation as a nidus for lymphoproliferative disorders. *Blood*. 2020 April 9;135(15):1303. PMID: 32271908
14. Chudasama R, **Hsu A**, Constantinou M. Orbital metastasis in inflammatory breast cancer. *Breast J*. 2020 Aug;26(8):1629-30. PMID: 32291824
15. **Hsu A**, Zayac AS, Eturi A, Almhanna K. Treatment for Metastatic Adenocarcinoma of the Stomach and Gastro-Esophageal Junction: 2020. *Ann Transl Med*. 2020 Sept; 8(17):1109. PMID 33145328
16. **Hsu A**, Chudasama R, Almhanna K, Raufi A. Targeted Therapies for Gastroesophageal Cancers. *Ann Transl Med*. 2020 Sept; 8(17):1104. PMID: 33145323
17. Alhames S, **Hsu A**, Rustam F, Kassab R, Shihade MB, Almhanna K. Esophageal cancer in Aleppo, Syria 2010-2020: a rare cancer in a war zone. *Ann Transl Med*. 2020 Sept; 8(17):1105. PMID: 33145324
18. **Hsu A**, Mistry H, Lala N, Reagan JL. Preliminary Findings Regarding the Use of Direct Oral Anticoagulants in Cerebral Venous Thrombosis. *Clin Neurol Neurosurg*. 2020 Nov; 198:106204. PMID: 32937276
19. Zayac AS, Hilliard RW, Olszewski AJ, Pelcovits A, Reagan JL, **Hsu A**, Riley D, Austin M, Ollila TA. Enforcing the “4T” through Implementation of a Hard Stop Calculator into the Electronic Medical Record. *R I Med J (2013)*. 2020 Oct 1;103(8):78-83. PMID: 33003686
20. **Hsu A**, Matera R, Dizon DS. Stewart-Treves Syndrome, a Rapidly Fatal Complication of Breast Cancer Treatment. *Lancet Oncol*. 2020 Oct;21(10):e495. PMID: 3302445
21. **Hsu A**, Freeman N. An Errant Sheep in Wolf’s Clothing. *R I Med J (2013)*. 2020 Nov 2;103(9):36-7. PMID: 33126786
22. **Hsu A**, Liu Y, Zayac AS, Olszewski AJ, Reagan JL. Intensity of Anticoagulation and Survival in Patients Hospitalized with COVID-19 Pneumonia. *Thromb Res*. 2020 Dec;196:375-8. PMID: 32980620
23. **Hsu A**, Matera R, Reagan JL, Farmakiotis D. Antifungal Prophylaxis During 7+3 Induction Chemotherapy for Acute Myeloid Leukemia is Associated with Improved Survival, in a Setting with Low Incidence of Invasive Mold Infections. *Support Care Cancer*. 2021 Feb; 29(2): 707-12. PMID: 32435969
24. **Hsu A**, Ohnigian S, Chang A, Liu Y, Zayac AS, Olszewski AJ, Reagan RL. Thrombosis in COVID-19: A Narrative Review of Current Literature and Inpatient Management. *R I Med J (2013)*. 2021 Jun 1;104(5):14-9. PMID: 34044431
25. Chudasama R, Phung Q, **Hsu A**, Almhanna K. Vaccines and immunotherapy for the treatment and prevention of gastrointestinal malignancies. *Vaccines (Basel)*. 2021 Jun; 9(6): 647. PMID: 34199248
26. **Hsu A**, Zayac A, Kurt H, Olszewski AJ. CD5 Expression in Marginal Zone Lymphoma Predicts Differential Response to Rituximab or Bendamustine/Rituximab. *Leuk Lymphoma*. 2021 Sep 1;1-12. PMID: 34467833
27. Olszewski AJ, Chorzalska AD, Petersen M, Ollila TA, Zayac AS, Kurt H, Treaba DO, Reagan JL, **Hsu A**, Egan PC, Butera J, Rafelson W, Niroula R, Vatevich J, Robison J, Sahin I, Mullins CD, Dubielecka PM. Cerebrospinal fluid analysis of clonotypic cfDNA as a diagnostic and prognostic marker of CNS invasion in aggressive lymphoma. *Blood Adv*. 2021 Dec 28;5(24):5525-35. PMID: 34551072

28. DeCarli K, Masel R, **Hsu A**, Lopresti M. Treatment-Induced Sarcoidosis in a Patient with Metastatic Clear Cell Ovarian Cancer. *BMJ Case Rep*. 2021 Dec 7;14(12):e247278. PMID: 34876449
29. Krane A, Selvaraj V, **Hsu A**. Atypical Presentation of Merkel Cell Carcinoma. *Brown J Hosp Med*. Published online May 1, 2022. DOI: 10.26300/6HFS-A866
30. Narendranath E, Zhao Q, Chowdhary SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Jordan Bruno X, Thomas C, Churnetski MC, **Hsu A**, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi P, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kothari S, Sawalha Y, Christian BA, David KA Greenwell BI, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio J, Barta SK, Grover NS, Ghosh N, Bartlett NL, Shouse G, Herrera A. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory marginal zone lymphoma: A multicenter cohort study. *J Hematol Oncol*. 2022 Jul 16;15(1):96. PMID: 35842643
31. Muthiah A, Ohnigian S, Reagan JR, **Hsu A**. Thrombosis in COVID 2022: An Updated Narrative Review of Current Literature and Inpatient Management. *R I Med J (2013)*. 2022 Aug 1;105(6):36-40. PMID: 35881999
32. **Hsu A**, Huntington K, De Souza A, Zhou L, Olszewski AJ, Makwana NP, Treaba DO, Cavalcante L, Giles FJ, Safran H, El-Deiry WS, Carneiro BA. Clinical activity of 9-ING-41, a selective glycogen synthase kinase-3 beta (GSK-3 β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. *Cancer Biol Ther*. 2022 Dec 31;23(1):417-23. PMID: 35815408
33. Narendranath E, Zhao Q, Chowdhary SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Jordan Bruno X, Thomas C, Churnetski MC, **Hsu A**, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi P, Torka P, Bello C, Ayyappan S, Karmali R, Oh T, Kim SH, Kress A, Kothari S, Sawalha Y, Christian BA, David KA Greenwell BI, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio J, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera A, Shouse G. Post-ibrutinib relapse outcomes for patients with marginal zone lymphoma. *Blood Adv*. 2022 Oct 21. PMID: 36269847
34. Tran TML, Chang A, Tran C, **Hsu A**. Metastatic Lung Cancer Presenting as Cutaneous Nodules. *R I Med J (2013)*. 2022 Nov 1;105(9):40-1. PMID: 36300964
35. Sanka P, **Hsu A**. A case of Pneumocystis jirovecii in a patient with non-small cell lung cancer treated with immunotherapy. *R I Med J (2013)*. 2023 Feb 1;106(1):11-3. PMID: 36706199
36. Hadfield MJ, Milrod CJ, **Hsu A**, Freeman N. Post-Transfusion Hemophagocytosis Without Evidence of Hemophagocytic Lymphohistiocytosis (HLH). *R I Med J (2013)*. 2023 Mar 1;106(2):20. PMID: 36848536
37. Phung QH, Masel R, Bijlani S, Tunzer JR, **Hsu A**, Almhanna K. Characterizing After-Hours Hematology/Oncology Clinic Calls. *Ann Palliat Med*. 2024 Jan;13(1):93-100. PMID: 38199799
38. Wadhavkar N, Nsubuga JP, Ibrahim N, Kumar P, **Hsu A**, Simmons S. Acute Liver Failure with Liver Enzymes > 5,000 in Sickle Cell Disease. *ACG Case Rep J*. 2024 Mar 20;11(3):e01303. PMID: 38511165

39. Moku P, **Hsu A**, Eappen K, Nadella M, Finn A. Warren Alpert Medical School of Brown University: Clinicopathologic Conference: September 20th, 2024. A Woman in her 20s with Abdominal Pain, Anemia and Thrombocytopenia. *J Brown Hosp Med*. 2025 Apr 1;4(2):6-10. PMID: 40191706
40. Trivedi C, **Hsu A**. A Review of Microangiopathic Hemolytic Anemia in Pregnancy. *J Brown Hosp Med*. 2025 July 1;4(3):137995. PMID: 40612089
41. Sun G, Eteshola EOU, Hadfield MJ, **Hsu A**. Acquired Hemophilia A After Neoadjuvant Immunotherapy for Renal Cell Carcinoma. *R I Med J (2013)*. 2026 Feb 2;109(2):14-8. PMID: 41592191
42. **Hsu A**, Fassett T, Pallagi S, Panch SR. Patient and Physician Experiences in Immune Thrombocytopenia. *Adv Ther*. 2026 Mar;43(3):935-47. PMID: 41591647

BOOK CHAPTERS

43. **Hsu A**, Raufi A. Chemotherapy Advances for the Treatment of Gastric Cancer. *Gastrointest Endosc Clin N Am*. 2021 Jul;31(3):607-623. PMID: 34053641

ABSTRACTS

1. **Hsu A**, Maheswaran A, Han S. A Tale of Two Tumors. Accepted for the Massachusetts Chapter, American College of Physicians (ACP) Abstract Competition 2015.
2. Holzwanger E, **Hsu A**, Al-Azzawi Y, Wassef W. A Case on Painless Jaundice in a Thirty-Three Year Old Gentleman. Accepted for the Massachusetts Chapter, American College of Physicians (ACP) Abstract Competition 2016.
3. Gagnier M, **Hsu A**, Hsu E. The Shifting Paradigm in the Treatment of Emphysematous Gastritis. Accepted for the European Congress of Clinical Case Report 2017.
4. **Hsu A**, Gagnier M, Hsu E, Gupta I, Trivedi M. The Changing Landscape in the Treatment of Emphysematous Gastritis. Accepted for the Society of Hospital Medicine's (SHM) Research, Innovations, and Clinical Vignettes 2017.
5. Bisallion J, Gagnier M, **Hsu A**, Trivedi M, Min J. Mycotic Aneurysm of Pulmonary Artery from Infective Endocarditis. Accepted for the Society of Hospital Medicine's (SHM) Research, Innovations, and Clinical Vignettes (RIV) 2017.
6. Holzwanger E, **Hsu A**, Hsu E, Gagnier M, Rupawala A, Pellish R. Emphysematous Gastritis: A Rare and Lethal Cause of Severe Abdominal Pain. Accepted for the World Congress of Gastroenterology at American College of Gastroenterology (ACG) 2017.
7. Hsu E, **Hsu A**. Hypercalcemia in Non-Hodgkin Lymphoma. Accepted for the Massachusetts Chapter, American College of Physicians (ACP) Abstract Competition 2017.
8. Matera R, Eteri A, **Hsu A**, Shimanovsky A, Dizon D. Stewart-Treves Syndrome, A Rare but Lethal Late Complication of Breast Cancer Treatment. Accepted for the Rhode Island Chapter, American College of Physicians (ACP) Abstract Competition 2019.
9. **Hsu A**, Matera R, Reagan JL, Farmakiotis D. Survival Benefits from Antifungal Prophylaxis and a Dedicated Inpatient Malignant Hematology Service during Induction Chemotherapy for Acute Myeloid Leukemia. Accepted for the American Society of Hematology (ASH) Annual Meeting and Exposition 2019. *Blood* (2019). 134 (Supplement_1): 3436.

10. Olszewski AJ, Chorzalska A, Kurt H, Ollila TA, Treaba DO, **Hsu A**, Zayac A, Reagan JL, Sahin I, Rafelson W, Egan PC, Robison J, Vatkevich J, Mullins CD, Petersen M, Dubielecka PM. Clonotypic cell-free DNA (cfDNA) in the cerebrospinal fluid (CSF) of patients with aggressive lymphomas. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 733.
11. **Hsu A**, Zayac A, Kurt H, Olszewski AJ. CD5+ Expression in Marginal Zone Lymphoma (MZL) Predicts Differential Response to Rituximab (R) or Bendamustine/Rituximab (BR). Accepted for the American Society of Hematology (ASH) 62nd Annual Meeting and Exposition 2020. *Blood* (2020). 136 (Supplement 1): 50-51.
12. Olszewski AJ, Chorzalska A, Peterson M, Ollila T, Zayac AS, Kurt H, Treaba D, Reagan JL, **Hsu A**, Egan PC, Butera J, Rafelson W, Niroula R, Robison J, Sahin I, Mullins C, Dubielecka PM. Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) as a Diagnostic and Prognostic Tool for Central Nervous System Invasion in Lymphoma. Submitted to the American Society of Hematology (ASH) Annual Meeting and Exposition 2020. *Blood* (2020). 136 (Supplement 1): 21–22.
13. Narendranath E, Zhao Q, Chowdhary SM, Moyo T, Shea L, Reddy N, Sheets J, Weiner D, Ramakrishnan P, Wilcox R, Bruno XJ, Thomas C, Churnetski M, **Hsu A**, Maakaron J, Caimi PF, Torka P, Bello C, David K, Lindsey K, Greenwell B, Evens A, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova ER, Awan F, Barta SK, Grover NS, Bartlet N, Ghosh N, Sawalha Y, Christian B, Herrera A, Shouse G. Predictive factors and outcomes for ibrutinib therapy in marginal zone lymphoma: a multicenter cohort study. Accepted for the American Society of Hematology (ASH) 62nd Annual Meeting and Exposition 2020. *Blood* (2020). 136 (Supplement 1): 35-36.
14. Chang A, **Hsu A**, Mega A. A Rare Case of Immunotherapy Induced Myocarditis and Myasthenia Gravis. Accepted for the American College of Physicians (ACP) Annual Meeting 2020.
15. Shah S, Sherif AA, **Hsu A**. Retrospective analysis of the effect of COVID-19 in hospitalized cancer patients. *Journal of Clinical Oncology* 41, no. 16_suppl (June 01, 2023) e18822-e18822.
16. Wadhavkar N, Nsubuga JP, Ibrahim N, Kumar P, **Hsu A**, Simmons S. Acute Liver Failure with Liver Enzymes > 5,000 in Sickle Cell Disease. Accepted for American College of Gastroenterology (ACG) Annual Scientific Meeting 2023.
17. Pou S, Trivedi C, Milrod CJ, **Hsu A**. Association of Platelet Count and Mean Platelet Volume with Severity of Bleeding Events in Immune Thrombocytopenia. Accepted for the American Society of Hematology (ASH) 66nd Annual Meeting and Exposition 2024. *Blood* (2024) 144 (Supplement 1): 1177.
18. Trivedi C, **Hsu A**, Quesenberry M. Balancing Bleeding and Thrombosis: Managing Acquired Hemophilia A in the Context of a Mechanical Aortic Valve. ISTH 2025 Congress: Thrombosis and Hemostasis Conference. Washington D.C.

INVITED PRESENTATIONS

REGIONAL

- Internal Medicine Residency Noon Conference at The Miriam Hospital, Providence, RI. “*Surrogate Endpoints in Oncology.*” January 18, 2022.
- Division of Hospital Medicine at Miriam Hospital Clinical Conference, Providence, RI. “*The Wonderful World of Direct Oral Anticoagulants (DOACs).*” May 10, 2022.
- Department of General Surgery Senior Education Conference, Providence, RI. “*Hypercoagulable Disorders and its Inpatient Management.*” May 17, 2022.
- Updates in Medicine for Providence Veterans Affairs Medical Center, Providence, RI. “*Updates in Chimeric Antigen Receptor (CAR) T-Cells for the Non-Hematologist.*” June 3, 2022.
- Interventional Radiology Morning Conference at Rhode Island Hospital, Providence, RI. “*IVC Filter and Other Topics in Management of VTE.*” August 25, 2022.
- Hematology/Oncology Fellowship Education Conference, Providence, RI. “*Hypercoagulable Testing and its Management.*” September 12, 2022.
- Lifespan Cancer Institute Mid-level (NP/PA) Education Conference, Providence, RI. “*Hypercoagulable States and its Management.*” December 12, 2022.
- Morbidity and Mortality: A 62-year-old female with thrombus straddling a patent foramen ovale (PFO). Invited panelist at Rhode Island Hospital Medical Grand Rounds. January 24, 2023.
- American College of Physicians, Rhode Island Chapter Annual Meeting. Providence, RI. “*Hematological Emergencies: Cytokine Release Syndrome and Neurotoxicity.*” March 15, 2023.
- Morbidity and Mortality: A 32-year-old male with acute right leg pain. Invited panelist at Rhode Island Hospital Medical Grand Rounds. July 25, 2023.
- Division of Hospital Medicine at Miriam Hospital Clinical Conference, Providence, RI. “*Thrombocytopenia in the Hospitalized Patient.*” August 8, 2023.
- eConsult & Enhanced Referral Co-Management Conference Series 2023. Providence, RI. “*Benign Hematology.*” November 9, 2023.
- Interventional Radiology Morning Conference at Rhode Island Hospital, Providence, RI. “*IVC Filter and Other Topics in Management of VTE.*” February 21, 2024.
- Rhode Island Academy of Family Physicians (RIAFP) Annual Primary Care Conference 2024. Providence, RI. “*Periprocedural Management of Anticoagulation and Antiplatelet Therapy in Primary Care.*” March 7, 2024.
- eConsult & Enhanced Referral Co-Management Conference Series 2024. Providence, RI. “*Benign Hematology.*” June 20, 2024.
- Morbidity and Mortality: *A Rash of Concerns: Skin Manifestations Following Heparin Therapy and Their Hidden Dangers.* Invited panelist at Rhode Island Hospital Medical Grand Rounds. January 7, 2025.
- Internal Medicine Residency Noon Conference at Rhode Island Hospital, Providence, RI. “*Hypercoagulable Testing and Venous Thromboembolism Management.*” March 24, 2025.
- American College of Physicians, Rhode Island Chapter Annual Meeting. Providence, RI.

"Hematological Emergencies: Cytokine Release Syndrome and Neurotoxicity." March 11, 2026.